Literature DB >> 24000251

Tiotropium Respimat increases the risk of mortality: pro.

Richard Beasley.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 24000251     DOI: 10.1183/09031936.00042113

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

Review 1.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

Review 2.  Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

3.  Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.

Authors:  Francesco Trotta; Roberto Da Cas; Maja Rajevic; Mariangela Rossi; Giuseppe Traversa
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

4.  Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.

Authors:  Ronald Dahl; Peter M A Calverley; Antonio Anzueto; Norbert Metzdorf; Andy Fowler; Achim Mueller; Robert Wise; Daniel Dusser
Journal:  BMJ Open       Date:  2015-12-29       Impact factor: 2.692

Review 5.  A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?

Authors:  Ronald Dahl; Alan Kaplan
Journal:  BMC Pulm Med       Date:  2016-10-11       Impact factor: 3.317

6.  Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.

Authors:  Francesco Trotta; Stefania Spila-Alegiani; Roberto Da Cas; Maja Rajevic; Valentino Conti; Mauro Venegoni; Mariangela Rossi; Giuseppe Traversa
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.